{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T21:40:25Z","timestamp":1718833225724},"reference-count":83,"publisher":"Impact Journals, LLC","issue":"46","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,11,15]]},"DOI":"10.18632\/oncotarget.12506","type":"journal-article","created":{"date-parts":[[2016,10,9]],"date-time":"2016-10-09T21:10:50Z","timestamp":1476047450000},"page":"74701-74723","source":"Crossref","is-referenced-by-count":2,"title":["Specificity and biologic activities of novel anti-membrane IgM antibodies"],"prefix":"10.18632","volume":"7","author":[{"given":"Rachel S.","family":"Welt","sequence":"first","affiliation":[{"name":"American Museum of Natural History, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan A.","family":"Welt","sequence":"additional","affiliation":[{"name":"Welt Bio-Molecular Pharmaceutical, LLC., Armonk, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Kostyal","sequence":"additional","affiliation":[{"name":"ARDL, Inc., Akron, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yamuna D.","family":"Gangadharan","sequence":"additional","affiliation":[{"name":"Welt Bio-Molecular Pharmaceutical, LLC., Armonk, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Raymond","sequence":"additional","affiliation":[{"name":"Welt Bio-Molecular Pharmaceutical, LLC., Armonk, NY, USA"},{"name":"Biogent, LLC., Armonk, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sydney","family":"Welt","sequence":"additional","affiliation":[{"name":"Welt Bio-Molecular Pharmaceutical, LLC., Armonk, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,10,9]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJM198203043060906","article-title":"Treatment of B cell lymphoma with monoclonal anti-idiotype antibody","volume":"306","author":"Levy","year":"1982","journal-title":"N Engl J Med"},{"key":"2","first-page":"61","article-title":"Therapy of lymphoma directed as idiotypes","volume":"10","author":"Miller","year":"1990","journal-title":"J Natl Cancer Inst Monographs"},{"key":"3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood.V79.1.129.129","article-title":"Monoclonal antibodies to idiotype inhibit in vitro growth of human B-cell lymphomas","volume":"79","author":"Moldenhauer","year":"1992","journal-title":"Blood"},{"key":"4","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood.V83.4.899.899","article-title":"Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein","volume":"83","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"5","first-page":"3176","article-title":"Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors","volume":"16","author":"Glennie","year":"1998","journal-title":"J Immunol"},{"key":"6","first-page":"691","article-title":"Cancer dormancy: role of cyclin-dependent kinase inhibitors in induction of cell cycle arrest mediated via membrane IgM","volume":"58","author":"Uhr","year":"1998","journal-title":"Cancer Res"},{"key":"7","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/sj.bjc.6690136","article-title":"Analysis of the interaction of monoclonal antibodies with surface IgM on neoplastic B-cells","volume":"79","author":"Glennie","year":"1999","journal-title":"Br J Cancer"},{"key":"8","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1182\/blood.V92.4.1184","article-title":"Anti-Idiotope antibodies can induce long term complete remissions in Non-Hodgkins Lymphoma without eradicating the malignant clone","volume":"92","author":"Levy","year":"1998","journal-title":"Blood"},{"key":"9","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1084\/jem.164.5.1566","article-title":"Idiotype variant cell populations in patients with B cell lymphoma","volume":"164","author":"Levy","year":"1986","journal-title":"J Exp Med"},{"key":"10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4049\/jimmunol.142.1.343","article-title":"Idiotype variants emerging after anti-idiotype monoclonal antibody therapy of a murine B cell lymphoma","volume":"142","author":"Kaminski","year":"1989","journal-title":"J Immunol"},{"key":"11","doi-asserted-by":"crossref","first-page":"752","DOI":"10.4049\/jimmunol.144.2.752","article-title":"Idiotypic variation in a human B lymphoma cell line","volume":"144","author":"Levy","year":"1990","journal-title":"J Immunol"},{"key":"12","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1182\/blood-2005-04-1483","article-title":"Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes","volume":"107","author":"Stilgenbauer","year":"2006","journal-title":"Blood"},{"key":"13","first-page":"5715","article-title":"Cutting Edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma","volume":"15","author":"Bondada","year":"2006","journal-title":"J Immunol"},{"key":"14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.immuni.2006.04.014","article-title":"The B cell receptor promotes B cell activation and proliferation through a non-ITAM tyrosine in the Ig\u03b1 cytoplasmic domain","volume":"25","author":"Rajewski","year":"2006","journal-title":"Immunity"},{"key":"15","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/ni.2116","article-title":"Endocytosed BCRs sequentially regulate MAPK and Akt signaling pathways from intracellular compartments","volume":"12","author":"Pierce","year":"2011","journal-title":"Nat Immunol"},{"key":"16","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with Ibrutinib in relapsed or refractory Mantle-Cell Lymphoma","volume":"369","author":"Radford","year":"2013","journal-title":"N Engl J Med"},{"key":"17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with Ibrutinib in relapsed Chronic Lymphocytic Leukemia","volume":"369","author":"Heerema","year":"2013","journal-title":"N Engl J Med"},{"key":"18","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's Tyrosine Kinase inhibitor Ibrutinib","volume":"370","author":"Yilmaz","year":"2014","journal-title":"N Engl J Med"},{"key":"19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.coi.2011.01.001","article-title":"Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation","volume":"23","author":"Rickert","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"20","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by Idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Davies","year":"2014","journal-title":"N Engl J Med"},{"key":"21","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.4049\/jimmunol.177.6.3597","article-title":"The extracellular membrane-proximal domain of human membrane IgE controls apoptotic signaling of the B cell receptor in the mature B cell line A20","volume":"177","author":"Burrone","year":"2006","journal-title":"J Immunol"},{"key":"22","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1007\/s12032-011-0025-7","article-title":"Trastuzumab and Lapatinib modulation of HER2 tyrosine\/threonine phosphorylation and cell signaling","volume":"29","author":"Welt","year":"2012","journal-title":"Med Oncol"},{"key":"23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/338383b0","article-title":"Antigen receptor tail clue","volume":"338","author":"Reth","year":"1989","journal-title":"Nature"},{"key":"24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/ni1547","article-title":"CD19 is essential for B cell activation by promoting B cell receptor-antigen microcluster formation in response to membrane-bound ligand","volume":"9","author":"Batista","year":"2008","journal-title":"Nature Immunol"},{"key":"25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.immuni.2008.11.007","article-title":"The constant region of the membrane immunoglobulin mediates B cell-receptor clustering and signaling in response to membrane antigens","volume":"30","author":"Pierce","year":"2009","journal-title":"Immunity"},{"key":"26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Susan","year":"2010","journal-title":"Nature"},{"key":"27","first-page":"155","article-title":"Conformation-induced oligomerization model for B cell receptor microclustering and signaling","volume":"340","author":"Pierce","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"key":"28","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2014.32.15_suppl.3050","article-title":"Antibody-mediated modulation of the IgM B-cell receptor (BCR) expression and signaling","volume":"32","author":"Welt","year":"2014","journal-title":"J Clin Oncol"},{"key":"29","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/nprot.2006.339","article-title":"Clonogenic assay of cells in vitro","volume":"1","author":"van Bree","year":"2006","journal-title":"Nature Protocols"},{"key":"30","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ccr.2011.06.029","article-title":"Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia","volume":"20","author":"Takenaka","year":"2011","journal-title":"Cancer Cell"},{"key":"31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrm2312","article-title":"Apoptosis: controlled demolition at cellular level","volume":"9","author":"Martin","year":"2008","journal-title":"Nat Rev Mol Biol"},{"key":"32","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1084\/jem.20042101","article-title":"Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells","volume":"201","author":"Wartenberg","year":"2005","journal-title":"J Exp Med"},{"key":"33","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2007-09-111344","article-title":"Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy","volume":"112","author":"Scielzo","year":"2008","journal-title":"Blood"},{"key":"34","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.semcancer.2010.08.004","article-title":"The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia","volume":"20","author":"Stevenson","year":"2010","journal-title":"Semin Cancer Biol"},{"key":"35","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrd3937","article-title":"Targeting pathological B cell receptor signalling in lymphoid malignancies","volume":"12","author":"Staudt","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"36","first-page":"3619","article-title":"Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma","volume":"2","author":"Ajchenbaum-Cymbalista","year":"2013","journal-title":"Exp Hematol Oncol"},{"key":"37","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.semcancer.2013.09.001","article-title":"B-cell receptor signaling as a driver of lymphoma development and evolution","volume":"23","author":"Wiestner","year":"2013","journal-title":"Semin Cancer Biol"},{"key":"38","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Stevenson","year":"1999","journal-title":"Blood"},{"key":"39","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1084\/jem.20040544","article-title":"Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia","volume":"200","author":"Chiorazzi","year":"2004","journal-title":"J Exp Med"},{"key":"40","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2004-01-0132","article-title":"Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia","volume":"104","author":"Roos","year":"2004","journal-title":"Blood"},{"key":"41","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1080\/10428190801959059","article-title":"Chronic lymphocytic leukemia with mutated IgVH1-69 usage: A distinct CLL subgroup with more indolent behavior?","volume":"49","author":"Rosenwald","year":"2008","journal-title":"Leuk Lymphoma Commentary"},{"key":"42","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/cncr.23671","article-title":"Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia","volume":"113","author":"Pinilla-Ibarz","year":"2008","journal-title":"Cancer"},{"key":"43","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nature11309","article-title":"Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signaling","volume":"489","author":"Veelken","year":"2012","journal-title":"Nature"},{"key":"44","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1182\/blood-2011-11-393694","article-title":"Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies","volume":"119","author":"Tichy","year":"2012","journal-title":"Blood"},{"key":"45","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1182\/asheducation-2014.1.125","article-title":"BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma","volume":"5","author":"Wiestner","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"46","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1182\/blood-2009-06-225326","article-title":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies","volume":"114","author":"Caligaris-Cappio","year":"2009","journal-title":"Blood"},{"key":"47","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-\u03baB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"Raghavachari","year":"2011","journal-title":"Blood"},{"key":"48","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3324\/haematol.2011.040659","article-title":"Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclearfactor \u03baB pathways","volume":"97","author":"Strair","year":"2012","journal-title":"Haematologica"},{"key":"49","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.cellsig.2012.03.008","article-title":"Interactions between bone marrow stromal microenvironment and B-chronic lymphocytic leukemia cells: Any role for Notch, Wnt and Hh signalling pathways","volume":"24","author":"Kamdje","year":"2012","journal-title":"Cellular Signaling"},{"key":"50","first-page":"113","article-title":"Stromal tumor microenvironment in Chronic Lymphocytic Leukemia: regulation of leukemic progression","volume":"1","author":"Joshi","year":"2013","journal-title":"J Leuk"},{"key":"51","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.hoc.2013.01.002","article-title":"Biology of Chronic Lymphocytic Leukemia in different microenvironments: clinical and therapeutic implications","volume":"27","author":"Wiestner","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"key":"52","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1002\/ijc.29326","article-title":"Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma","volume":"136","author":"Baran-Marszak","year":"2015","journal-title":"Int J Cancer"},{"key":"53","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2013-09-527853","article-title":"Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy","volume":"123","author":"Mantel","year":"2014","journal-title":"Blood"},{"key":"54","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1182\/blood-2013-02-482125","article-title":"Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients","volume":"122","author":"Spaargaren","year":"2013","journal-title":"Blood"},{"key":"55","first-page":"179","article-title":"Treatment of chronic myelogenous leukemia as a paradigm for solid tumors: how targeted agents in newly diagnosed disease transformed outcomes","author":"Kurzrock","year":"2012","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"56","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Wright","year":"2010","journal-title":"Nature"},{"key":"57","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.4049\/jimmunol.158.7.3062","article-title":"Membrane IgM-induced tyrosine phosphorylation of CD19 requires a CD19 domain that mediates association with component of the B cell receptor complex","volume":"158","author":"Fearon","year":"1997","journal-title":"J Immunol"},{"key":"58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1074-7613(00)80511-7","article-title":"Characterization of the B lymphocyte populations in Lyn deficient mice and the role of Lyn signal initiation and down regulation","volume":"7","author":"Lowell","year":"1997","journal-title":"Immunity"},{"key":"59","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1084\/jem.187.8.1343","article-title":"A double-edged kinase Lyn: a positive and negative regulator for antigen receptor-mediated signals","volume":"187","author":"Yamamoto","year":"1998","journal-title":"J Exp Med"},{"key":"60","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cell.2009.08.041","article-title":"PI3 kinase signals BCR dependent mature B cell survival","volume":"139","author":"Rajewsky","year":"2009","journal-title":"Cell"},{"key":"61","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.coi.2011.01.001","article-title":"Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation","volume":"23","author":"Rickert","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"62","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4049\/jimmunol.163.1.137","article-title":"The guanine-nucleotide exchange factor Vav is a crucial regulator of B cell receptor activation and B cell responses to nonrepetitive antigens","volume":"163","author":"Penninger","year":"1999","journal-title":"J Immunol"},{"key":"63","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/eji.200939848","article-title":"Differential phosphorylation of functional tyrosines in CD19 modulates B-lymphocyte activation","volume":"40","author":"Fujimoto","year":"2010","journal-title":"Eur J Immunol"},{"key":"64","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1126\/science.7618087","article-title":"A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP","volume":"269","author":"Fearon","year":"1995","journal-title":"Science"},{"key":"65","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1126\/science.274.5288.798","article-title":"Hyperresponsive B cells in CD22-deficient mice","volume":"274","author":"Neuberger","year":"1996","journal-title":"Science"},{"key":"66","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/384634a0","article-title":"CD22 regulates thymus-independent response and the lifespan of B cells","volume":"384","author":"Clark","year":"1996","journal-title":"Nature"},{"key":"67","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.4049\/jimmunol.159.7.3278","article-title":"Regulation of B lymphocyte development and activation by the CD19\/CD21\/CD81\/Leu13 complex requires the cytoplasmic domain of CD19","volume":"159","author":"Tedder","year":"1997","journal-title":"J Immunol"},{"key":"68","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1084\/jem.187.5.807","article-title":"Inhibition of B-cell by CD22: a requirement for Lyn","volume":"187","author":"Fearon","year":"1998","journal-title":"J Exp Med"},{"key":"69","first-page":"195","article-title":"Receptor modulators of B-cell receptor signaling-CD19\/22","volume":"245","author":"Fearon","year":"2000","journal-title":"Curr Top Microbiol Immunol"},{"key":"70","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.4049\/jimmunol.174.6.3264","article-title":"Coligation of the B cell receptor with complement receptor type 2 (CR2\/CD21) using its natural ligand C3dg: activation without engagement of an inhibitory signaling pathway","volume":"174","author":"Holers","year":"2005","journal-title":"J Immunol"},{"key":"71","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.4049\/jimmunol.175.12.8011","article-title":"Complement component C3d-antigen complexes can either augment or inhibit B lymphocyte activation and humoral immunity in mice depending on the degree of CD21\/CD19 complex engagement","volume":"175","author":"Tedder","year":"2005","journal-title":"J Immunol"},{"key":"72","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1158\/0008-5472.CAN-08-2250","article-title":"Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection","volume":"69","author":"Gray","year":"2009","journal-title":"Cancer Res"},{"key":"73","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial","volume":"16","author":"Lipsky","year":"2015","journal-title":"Lancet Oncol"},{"key":"74","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","article-title":"Construction and pre-clinical evaluation of an anti-CD19 chimeric antigen receptor","volume":"32","author":"Rosenberg","year":"2009","journal-title":"J Immunother"},{"key":"75","first-page":"63","article-title":"Blinatumomab, a bi-specific anti-CD19\/CD3 BiTE\u00ae antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications","volume":"4","author":"Gore","year":"2014","journal-title":"Front Oncol"},{"key":"76","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.bbapap.2007.10.006","article-title":"The possible interaction of CDA14 and protein elongation factor 1\u03b1","volume":"1784","author":"Tseng","year":"2008","journal-title":"BBA-Proteins Proteom"},{"key":"77","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/(SICI)1097-0215(19960208)65:4<406::AID-IJC2>3.0.CO;2-0","article-title":"Serological and immunochemical analysis of Lewis Y (Ley) blood group antigen expression in epithelial ovarian cancer","volume":"65","author":"Lloyd","year":"1996","journal-title":"Int J Cancer"},{"key":"78","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.4049\/jimmunol.180.8.5499","article-title":"Targeting the extra-cellular membrane proximal domain of membrane-bound IgE by passive immunization blocks IgE synthesis in vivo","volume":"180","author":"Achatz","year":"2008","journal-title":"J Immunol"},{"key":"79","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.4049\/jimmunol.0902437","article-title":"Unique epitopes on C\u03b5mX in IgE-B cell receptors are potentially applicable for targeting IgE-committed B cells","volume":"184","author":"Yung","year":"2010","journal-title":"J Immunol"},{"key":"80","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1073\/pnas.73.9.3278","article-title":"Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells","volume":"73","author":"Old","year":"1976","journal-title":"Proc Natl Acad Sci U S A"},{"key":"81","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1089\/hyb.1996.15.401","article-title":"Specificity analysis of murine monoclonal antibodies reactive with Tn, sialylated Tn, T, and monosialylated (2\u21926) T antigens","volume":"15","author":"Wright","year":"1996","journal-title":"Hybridoma"},{"key":"82","doi-asserted-by":"crossref","first-page":"13668","DOI":"10.1074\/jbc.275.18.13668","article-title":"The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies","volume":"275","author":"Barbas","year":"2000","journal-title":"J Biol Chem"},{"key":"83","first-page":"1052","article-title":"Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody","volume":"37","author":"Willingham","year":"1996","journal-title":"J Nucl Med"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T21:04:57Z","timestamp":1718831097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,9]]},"references-count":83,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2016,11,15]]}},"alternative-id":["12506","27732950"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.12506","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,9]]}}}